SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
19.70
+0.10 (0.51%)
At close: Feb 27, 2026
14.07%
Market Cap 1.05B
Revenue (ttm) n/a
Net Income (ttm) -110.83M
Shares Out 53.12M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE 5.24
Dividend n/a
Ex-Dividend Date n/a
Volume 57,658
Average Volume 141,241
Open 19.66
Previous Close 19.60
Day's Range 19.40 - 20.00
52-Week Range 13.40 - 25.30
Beta 1.06
RSI 46.16
Earnings Date Feb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.